Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC21706 STX3451 A non-steroidal sulphamate analogue of 2-methoxyoestradiol (2ME2) and microtubule disruptor, shows anti-proliferative activity against NCI 60 cell lines with mean GI50 of 50 nM.
DC11919 Arimoclomol Featured A nontoxic heat shock protein (HSP) coinducer and potentiator of the heat shock response.
DC11920 Arimoclomol maleate Featured A nontoxic, orally active heat shock protein (HSP) coinducer and potentiator of the heat shock response.
DC24034 Coluracetam A nootropic agent that enhances high-affinity choline uptake.
DC21342 MPT0L145 A nove potent, dual FGFR and PIK3C3 inhibitor with Kd of 0.53 nM for PIK3C3.
DC20550 SHP2 inhibitor 2 A nove potent, selective and reversible SHP2 inhibitor with Ki of 0.51 uM.
DC11523 Landipirdine A novel 5-HT receptor antagonist for the treatment of Parkinson's disease..
DC11793 UMB-32 A novel a potent, selective inhibitor of BRD4 with Kd of 550 nM, cellular IC50 of 724 nM.
DC23493 Ladarixin A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
DC23467 Ladarixin sodium A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
DC20706 AVN-211 A novel and highly selective 5-HT6 receptor small molecule antagonist with Ki of 2.34 nM.
DC22565 K-Ras G12C-IN-3 A novel and irreversible inhibitor of mutant K-ras G12C..
DC22572 K-Ras G12C-IN-2 A novel and irreversible inhibitor of mutant K-ras G12C..
DC22573 K-Ras G12C-IN-1 A novel and irreversible inhibitor of mutant K-ras G12C..
DC22587 FT011 Featured FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis.
DC11888 Arfolitixorin A novel antifolate modulator compound..
DC22391 Olorofim(F-901318) Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp.
DC11998 IND-114338 A novel antiprion compound with EC50 of 68 nM, significantly increases monoglycosylated/diglycosylated PrPSc..
DC11534 Sudoterb Featured A novel anti-TB agent that has an MIC range of 0.06-0.5 ug/mL..
DC11535 Sudoterb dihydrchloride A novel anti-TB agent that has an MIC range of 0.06-0.5 ug/mL..
DC11663 GS-5759 A novel bifunctional PDE4 inhibitor (IC50=5 nM) and long acting β2-adrenoceptor agonist (EC50=8 nM).
DC11997 IND125 A novel brain penetrant antiprion compound with EC50 of 57 nM, prevents both PrP(Sc) accumulation and astrocytic gliosis in the cerebrum.
DC11792 UMB-136 A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation.
DC22507 SCH-00013 A novel cardiotonic agent that acts as a calcium sensitizer with no chronotropic activity in mammalian cardiac muscle, elicits positive inotropic effect in dog and rabbit ventricular muscles (EC50=9.2 uM).
DC11785 IHR-1 A novel cell membrane impermeable smoothened antagonist with IC50 of 7.6 nM in Hh-dependent Gli transcriptional activity assay.
DC11784 IHR-Nac A novel cell permeable smoothened antagonist with IC50 of 3.1 nM in Hh-dependent Gli transcriptional activity assay.
DC22789 5S rRNA modificator 2 A novel chemical probe that enable selective 2’-hydroxyl acylation for accurate RNA structural analysis in living cells..
DC11628 HIV-1 Integrase Inhibitor 1 A novel compound that disrupts the HIV-1 integrase LEDGF interaction.
DC11521 Dotinurad Featured Dotinurad is a novel compound that exhibits a remarkable uric acid excretion-promoting action.
DC20796 BIOD303 A novel conformational modulator of α-synuclein with EC50 of 105 uM, potentially outcompetes spermine in binding to α-synuclein.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X